GlassScriptPhysician profile
Robert Michael Rajczy
NPI 1689985434
$1,972.62
in general payments reported to CMS, 2019-2025
25 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $60.95 · 2021: $250 · 2022: $168 · 2023: $376 · 2024: $310 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $274.76 | 2019-2025 | N/A, Fuseforce, Ortholoc 3di |
| Zimmer Biomet Holdings, INC. | $156.97 | 2021-2024 | Tapestry |
| Wright Medical Technology, INC. | $142.53 | 2019 | |
| Smith+Nephew, INC. | $141.58 | 2019-2022 | |
| Treace Medical Concepts, INC. | $136.98 | 2023-2025 | |
| Convatec INC. | $128.60 | 2025 | |
| Organogenesis INC. | $122.34 | 2021-2023 | Puraply |
| Paratek Pharmaceuticals, INC. | $118.49 | 2023-2025 | Nuzyra |
| Vaporox, INC. | $111.33 | 2023 | Vht-200 Wound Treatment System |
| Integra Lifesciences Corporation | $95.58 | 2019-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medtronic, INC. | $95.40 | 2023 | Intellis Adaptivestim |
| Averitas Pharma INC. | $84.28 | 2024 | Qutenza |
| Bioventus LLC | $56.33 | 2019 | |
| Zimvie INC. | $49.95 | 2023 | |
| Depuy Synthes Sales INC. | $39.30 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acera Surgical, INC. | $32.91 | 2022 | |
| Kerecis Limited | $27.74 | 2019 | |
| Mimedx Group, INC. | $27.14 | 2025 | |
| Solventum Corporation | $22.35 | 2025 | Activ.A.C., 3m Coban, Promogran Prisma |
| Pacira Pharmaceuticals Incorporated | $22.02 | 2024 | Exparel |
| Nalu Medical, INC. | $19.93 | 2025 | Nalu Neurostimulation System |
| Ibsa Pharma INC. | $19.23 | 2024 | Tirosint, Licart |
| Nevro Corp. | $17.61 | 2023 | Senza |
| Orthofix Medical, INC. | $15.25 | 2025 | Physio-Stim |
| Merck Sharp & Dohme LLC | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rajczy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.